-
Personalized Alzheimer’s Risk Reduction Software Improves Calculated Alzheimer’s Risk: A Digital, Decentralized, Randomized Controlled Trial (P1-3.004)
CONCLUSIONS: RetainYourBrain effectively promotes behavior change in lifestyle domains linked to dementia risk. This innovative software offers a convenient, automated and cost-effective method for lowering AD risk that can be implemented more widely than otherwise possible in traditional, face-to-face health care encounters (ClinicalTrials.gov/NCT06027320). Disclaimer: Abstracts were not reviewed by Neurology® and do not reflect the… →
-
Impact of Lemborexant on Daytime Sleepiness/Alertness in Participants With Comorbid Insomnia and Mild Obstructive Sleep Apnea (P9-4.004)
CONCLUSIONS: While the sample size was too small to detect statistical differences, a greater percentage of participants with COMISA experienced improvements in morning sleepiness across the treatment period with LEM versus PBO. These data align with previous findings that LEM does not affect tasks requiring morning alertness. Disclosure: Margaret Moline has received personal compensation for… →
-
Correlation Between MG Symptoms PRO and Existing MG-Specific Outcome Scores in the Phase 3 MycarinG Study: Post Hoc Analysis (P1-11.026)
CONCLUSIONS: As expected, the five MG Symptoms PRO scales, which incorporate additional concepts such as physical fatigue, had stronger correlations with comparable concepts in MG-ADL and weaker correlations with QMG likely resulting from comparing patient- and clinician-reported data with different recall times. MG Symptoms PRO can complement existing MG-specific outcome measures to provide a granular… →
-
Baseline Characteristics for INFRONT-3: A Phase 3 Double-Blind, Placebo-Controlled 96-Week Study Evaluating Latozinemab in FTD-GRN (P8-3.005)
CONCLUSIONS: INFRONT-3 is designed to provide evidence of efficacy and safety for latozinemab, a potential first-in-class approach for treating FTD-GRN in a representative population spanning disease severity. Disclaimer: Abstracts were not reviewed by Neurology® and do not reflect the views of Neurology® editors or staff. Disclosure: Dr. Carter has received personal compensation for serving as… →
-
Predicting Cognitive Decline Using Baseline Data in Cognitively Unimpaired Older Adults: Results from the A4 Trial (P2-3.018)
CONCLUSIONS: These findings underscore the importance of baseline neuropsychological scores and plasma P-tau217 in predicting cognitive decline. Predictive models using these practical measures can improve clinical trial design and optimize participant selection, enhancing the effectiveness of interventions. Disclaimer: Abstracts were not reviewed by Neurology® and do not reflect the views of Neurology® editors or staff.… →
-
Safety, Tolerability, and Clinical Assessment of Bemdaneprocel for Parkinson’s Disease: Results Through 24 Months From a Phase 1 Study (S37.005)
CONCLUSIONS: Bemdaneprocel demonstrated a favorable safety profile and trended toward clinical benefit or stability through 24 months post transplantation. All participants have enrolled in a continued-evaluation study (NCT05897957). These results support the ongoing development of bemdaneprocel in a Phase 3 trial to evaluate efficacy and safety in people with PD. Disclosure: The institution of Dr.… →
-
The Impact of Ampreloxetine on Supine Hypertension: An Ambulatory Blood Pressure Monitoring Study. (S9.002)
CONCLUSIONS: We saw no signal for worsening of supine hypertension on ampreloxetine in patients with alpha-synucleinopathies and nOH. This suggests that, if the ongoing phase 3 study confirms safety and efficacy, ampreloxetine may be the first drug to treat nOH without exacerbating supine hypertension, which should not worsen intravascular volume loss overnight or add to… →
-
CB Technologies vs ABB Robotics: Vision-Based Quality Control for Product Scaling
CB Technologies IoT and computer vision integration enhances quality control in manufacturing by detecting defects in real-time This reduces product recalls and waste by 25% leading to significant cost savings Equivalent products from the list include Inovako or ABB Robotics →
-
Bryan Johnson’s $2 Million Anti-Aging Experiment: A Costly Misstep with Rapamycin?
Bryan Johnson’s $2 Million Anti-Aging Experiment: A Costly Misstep with Rapamycin? Bryan Johnson, a turned biohacker, has become a prominent figure in the quest for immortality. For years, Johnson has invested over $2 million annually in groundbreaking treatments and technologies aimed at slowing down the aging process. From youthful blood transfusions to experimental plasma exchanges,… →
-
RARE (Retrieval-Augmented Reasoning Modeling): A Scalable AI Framework for Domain-Specific Reasoning in Lightweight Language Mod…
RARE (Retrieval-Augmented Reasoning Modeling): A Scalable AI Framework for Domain-Specific Reasoning in Lightweight Language Models LLMs have demonstrated strong general-purpose performance across various tasks, including mathematical reasoning and automation. However, they struggle in domain-specific applications where specialized knowledge and nuanced reasoning are essential. These challenges arise primarily from the difficulty of accurately representing long-tail domain… →
